2011
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
Mayer‐Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch‐Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, Investigators F. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology 2011, 47: 125-134. PMID: 21830317, PMCID: PMC3214247, DOI: 10.1002/ppul.21525.Peer-Reviewed Original ResearchConceptsExacerbation riskInitial eradicationCystic fibrosisPseudomonas aeruginosa acquisitionInitial antibiotic treatmentPositive respiratory culturesPA recurrenceProportional hazards modelSymptom-based definitionEPIC trialPulmonary exacerbationsAntibiotic therapyTreatment failureClinical benefitPA infectionRespiratory culturesSubsequent exacerbationAntibiotic treatmentEarly eradicationHigh riskNegative culturesExacerbationHazards modelSignificant predictorsTrials
2009
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, Group E. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. Contemporary Clinical Trials 2009, 30: 256-268. PMID: 19470318, PMCID: PMC2783320, DOI: 10.1016/j.cct.2009.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAnti-Bacterial AgentsChildChild, PreschoolCiprofloxacinCohort StudiesCystic FibrosisDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInfantLongitudinal StudiesMalePseudomonas aeruginosaPseudomonas InfectionsRisk FactorsTobramycinTreatment OutcomeConceptsEarly Pa infectionYoung CF patientsRespiratory culturesRisk factorsCystic fibrosisCohort studyPA infectionClinical trialsObservational studyCF patientsEarly CF lung diseaseProgressive obstructive pulmonary diseaseProportion of patientsClinical efficacy dataObstructive pulmonary diseasePositive respiratory culturesPatients ages 1Longitudinal cohort studyCF lung diseaseChronic endobronchial infectionInfection control programPa acquisitionPA-negative patientsOral ciprofloxacinOral placebo